Fangshenghe Pharma Completes Series B Funding Round Led by Jinyuan Capital and Kaitai Capital

VCBeat (WeChat ID: vcbeat) learned that on March 20, Nanjing F&S Pharma Tech Co., Ltd. (hereinafter referred to as “F&S Pharma” or the “Company”) announced the completion of its Series B financing round. The round was led by Jinyuan Capital and Kaitai Capital, with Xuzhou Guosheng Group and Zhengxinhe Investment Management Co., Ltd. participating as co-investors. Existing shareholder BGI Win-Win continued to increase its investment in this round, marking the Company’s fourth financing round completed over the past three years.

Leveraging the power of capital, the company will continue to integrate resources and technological innovation together with its strategic partners, strengthen its R&D pipeline layout, and deepen collaboration with physical entities. This aims to further improve its R&D and industrialization platform, and fulfill the mission of “making quality medicines accessible and affordable to the public at an earlier stage” by utilizing the Marketing Authorization Holder (MAH) system in compliance with Chinese laws and regulations. The company currently has eight products in its pipeline, two of which submitted marketing applications in 2018 and are expected to be approved this year.

In October 2015, with strong support from the Pukou District Government and the Pukou Economic Development Zone, F&S Pharma Tech was jointly established by its founding team, Suzhou CrystalPharm Drug Technology Co., Ltd., and Bank of Nanjing, and officially commenced operations in June 2016. Currently, the company operates a 5,000-square-meter R&D center and has formed a joint venture with Jiangsu Yongda Pharmaceutical Co., Ltd.

To date, the company has been recognized as a National High-Tech Enterprise, a Jiangsu Province “Little Giant” Enterprise, a Nanjing City Cultivated Unicorn Enterprise, a Jiangsu Province Technology-Based Small and Medium-sized Enterprise, and a Jiangsu Province Private Science and Technology Enterprise. It was also successfully selected as one of the first batch of “Xiao Lingque” enterprises in the Nanjing Jiangbei New Area. In 2016, the company became one of the first domestic clients of Nanjing Bank’s “Investment-Loan Linkage” program. In 2019, the company partnered with The People’s Insurance Company (Group) of China Limited (PICC) to launch China’s first “Technology Project R&D Expense Loss Insurance” policy, providing coverage for the uncertainties inherent in pharmaceutical research and development.

Jinyuan Capital Management (Xiamen) Co., Ltd. is an integrated investment management platform under Jinyuan Group, specializing in private equity investment, capital markets, and fixed-income investment. To date, the company has initiated and established the Jinyuan Equity Direct Investment Fund and multiple equity investment cooperation funds, leveraging capital to support the development of the real economy. As a state-owned financial holding group under the Xiamen Municipal Government, Jinyuan Group’s business spans securities, trust, funds, venture capital, asset management, and national-level credit financing service platforms. It is committed to providing comprehensive financial services throughout the entire lifecycle of enterprises. In February 2020, it initiated the establishment of Jinyuan Unity Securities Co., Ltd., the first cross-strait joint venture securities company.

Kaitai Capital, established in 2009, is a professional venture capital management firm. It primarily engages in innovation investment, industrial investment, and financial management services, with investment focus areas including life sciences and general health, artificial intelligence and digital technology, as well as community innovation and consumption upgrading. To date, the total assets under management by Kaitai Capital have exceeded RMB 50 billion.

Xuzhou Guosheng Holding Group Co., Ltd. is a wholly state-owned platform company established with the approval of the Xuzhou Municipal People’s Government. Aligning with its functional positioning as a “financial service platform,” Guosheng Group has established three core business segments: financial services, fund management, and asset management. The group owns 12 wholly-owned subsidiaries and holds equity interests in 26 companies. It holds financial licenses for financing guarantees, fund management, technology-focused microcredit, asset management companies (AMCs), and financial leasing.

Co-founded by BGI Group and leading life sciences investment teams active in the Asia-Pacific region, the firm is committed to becoming a premier industrial fund investment management institution in the life and health sector. It strategically invests across the ecosystem of the broader health industry, focusing on biopharmaceuticals, technology, and bio-agriculture. By leveraging substantial industrial resources in life sciences, along with exceptional capabilities in investment analysis and active portfolio management, the firm effectively enhances investment returns while mitigating risks.

The company focuses on unlisted enterprises in their growth, expansion, and maturity stages that align with national industrial policy support. It prioritizes sectors such as TMT (Information Technology), healthcare and wellness, environmental protection, consumption upgrades, and education. The firm has participated in projects like “Intretech” and achieved successful exits.